Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

Korábbi kezelés

• Prior WBRT for brain metastases (prior stereotactic radiosurgery for parenchymal CNS metastases received <7 days prior to consent );
• Prior therapy specifically directed at LMD, including prior radiotherapy or systemic therapy;
• Prior use of tucatinib at any time prior to enrollment.
• Use of a strong cytochrome P450 (CYP)2C8 inhibitor within 5 half-lives of the inhibitor or use of a strong CYP3A4 or CYP2C8 inducer within 5 days prior to the first dose of systemic therapy (see Appendix C and D);
• Myocardial infarction or unstable angina within 6 months prior to the first dose of systemic therapy.

Más betegség

• Inability to comply with MRI-based surveillance of CNS disease;
• Inability to swallow pills or any significant gastrointestinal diseases such as inflammatory bowel disease who suffer from uncontrolled diarrhea (based on the investigator's assessment),, which would preclude adequate absorption of oral medications;
• Diagnosed with Gilbert's disease;
• Prior history of other cancer (except non melanoma skin, cervical intraepithelial neoplasia) with evidence of disease within the last 5 years;
• Hypersensitivity to any of the active substances in tucatinib, trastuzumab, or capecitabine.
  • Phase 2:

Egyéb

• Diagnosed with Hereditary fructose intolerance;
• Currently pregnant or breastfeeding;
• Blood product transfusions in order to meet eligibility criteria

• Men or women with HER2+, HER2 mutated and/or HER2-amplified metastatic breast cancer. HER2+ status will be defined in accordance with ASCO-CAP 2018 guidelines, and can be diagnosed at any time prior to enrolment. HER2 mutations and/or HER2-amplifications can be identified in the blood and/or cerebrospinal fluid (CSF) at any time prior to enrolment; testing blood and/or CSF is not part of the study protocol and must be evaluated using a clinically validated test.
• Evidence of LMD* in the brain and/or spine (either positive cerebral spinal fluid cytology and/or magnetic resonance imaging evidence of LMD). Measurable disease in the central nervous system is not required. * The diagnosis of LMD can occur at any time prior to enrolment;
• Age 18+ at time of consent;
• ECOG ≤ 2;
• More than 14 days or 5 half-lives from the last dose of any experimental agent is required, whichever is greater;
• All toxicity related to prior cancer therapies must have resolved to ≤ Grade 1 prior to enrollment, except for alopecia; neuropathy, must have resolved to ≤ Grade 2.
  • Phase 2: Inclusion Criteria
• Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by ECHO or MUGA documented within 2 weeks prior to starting systemic therapy on the study;
• Adequate hematologic, liver, and renal function within 2 weeks prior to phase 2 enrollment, as follows:
  • Hemoglobin ≥ 9 g/dL
  • ANC ≥ 1 x109/L
  • Platelets ≥ 100 x109/L
  • Total bilirubin ≤ 1.5 X upper limit of normal (ULN)
  • AST and ALT ≤ 2.5X ULN
  • International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 X ULN
  • Creatinine clearance (CrCL) ≥ 50 mL/min
• The last dose of prior therapy must have been completed 14 days prior to study enrollment. Prior chemotherapy, immunotherapy, endocrine therapy, targeted therapy and experimental agents are allowed (including prior use of trastuzumab or other antibody-based therapy). Prior use of capecitabine either alone or in combination with other HER2-targeted therapies (including other tyrosine kinase inhibitors) is permitted;